COH-SR4 is anAMPK activator with anticancer properties. It significantly inhibited adipocyte differentiation in a dose-dependent manner in 3T3-L1 cells. It significantly reduced intracellular lipid accumulation and downregulated the expression of key adipogenesis-related transcription factors and lipogenic proteins in differentiating adipocytes.
COH-SR4 activates AMPK and exhibits strong anti-proliferative effects against leukemia, melanoma, breast, and lung cancers. It hinders adipocyte differentiation by activating AMPK. COH-SR4 is a valuable tool for studying obesity and associated metabolic disorders[1].
体内研究
COH-SR4 (5 mg/kg; i.g.; 3x/week; for 6 weeks) decreases body weight and fat mass in high-fat diet (HFD) obese mice without impacting food intake[2].
COH-SR4 enhances glycemic control and improves dyslipidemia in high-fat diet (HFD) obese mice[2].
COH-SR4 reduces adipose tissue hypertrophy and influences circulating adipokine levels in high-fat diet (HFD) obese mice[2].
COH-SR4 inhibits the build-up of hepatic lipids and fatty liver in obese mice on a high-fat diet (HFD)[2].
体外研究
COH-SR4 (1-5 μM; 24 hours) induces a dose-dependent rise in AMPK phosphorylation and its substrate ACC in 3T3-L1 preadipocytes, as well as in cancer cells like HL-60, HeLa, MCF-7[1].
COH-SR4 (3-5 µM; 7 days) effectively inhibits the differentiation of 3T3-L1 adipocytes in a dose-dependent manner[1].
COH-SR4 markedly decreases intracellular lipid accumulation and suppresses the expression of crucial adipogenesis-related transcription factors and lipogenic proteins[1].
搜索
